Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
The confirmed malignant tumor is one of the non-small cell lung cancer/small cell lung cancer/breast cancer/gastric cancer/esophageal cancer/colorectal cancer/gynecological malignant tumor (ovarian cancer, cervical cancer, endometrial cancer).
Patients who need to receive chemotherapy in the past 3 months and should continue to receive chemotherapy in the future
The relevant diagnosis and treatment information involved in the survey is complete: only patients with at least 1-2 examination results after 1 week after chemotherapy can be included
Understand and sign the informed consent form
Patients with concurrent chemoradiotherapy,
Patients with sequential chemoradiotherapy, and the irradiation site of radiotherapy is flat bone, sternum, and pelvis;
Patients with active bleeding before or during treatment; If the patient has received targeted drugs such as CDK4/6 inhibitors or chidaaniline in the front-line treatment, which have a great impact on the blood phase, the drug can be discontinued for at least half a month before it can be included
Patients who, in the opinion of other physicians, would cause non-chemotherapy-related myelosuppression
The First Affiliated Hospital of Xinxiang Medical College
Lead sponsor
Xinxiang Central Hospital of Henan province
Collaborator
Linzhou People Hospital
Collaborator
Inner Huang County Traditional Chinese Hospital
Collaborator
Changyuan People Hospital
Collaborator
Huojia County People Hospital
Collaborator
Huojia County Alliance Hospital
Collaborator
Qinyang People Hospital
Collaborator
Xinan County People Hospital
Collaborator
Henan Hongli Hospital
Collaborator
Army Hospital of the 83rd Army
Collaborator
Anyang Cancer Hospital
Collaborator
Puyang Hospital of Traditional Chinese Medicine
Collaborator
Puyang Huimin Hospital
Collaborator
Hebi People Hospital
Collaborator
The Second People Hospital of Xinxiang Henan
Collaborator